ICECURE MEDICAL LTD (ICCM)
IL0011224156 - Common Stock
We assign a fundamental rating of 3 out of 10 to ICCM. ICCM was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While ICCM seems to be doing ok healthwise, there are quite some concerns on its profitability. ICCM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ICCM had negative earnings in the past year.
In the past year ICCM has reported a negative cash flow from operations.
ICCM had negative earnings in each of the past 5 years.
ICCM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -90.55%, ICCM is doing worse than 81.48% of the companies in the same industry.
ICCM has a worse Return On Equity (-137.51%) than 70.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.55% | ||
| ROE | -137.51% | ||
| ROIC | N/A |
ROA(3y)-58.73%
ROA(5y)-55.17%
ROE(3y)-74.66%
ROE(5y)-93.29%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 43.67%, ICCM is doing worse than 63.49% of the companies in the same industry.
ICCM's Gross Margin has been stable in the last couple of years.
ICCM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.89%
GM growth 5Y-0.83%
2. Health
2.1 Basic Checks
ICCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICCM has been increased compared to 1 year ago.
Compared to 5 years ago, ICCM has more shares outstanding
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ICCM has an Altman-Z score of -3.69. This is a bad value and indicates that ICCM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.69, ICCM is not doing good in the industry: 67.72% of the companies in the same industry are doing better.
ICCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.69 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
A Current Ratio of 2.67 indicates that ICCM has no problem at all paying its short term obligations.
ICCM has a Current ratio (2.67) which is in line with its industry peers.
A Quick Ratio of 2.27 indicates that ICCM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.27, ICCM perfoms like the industry average, outperforming 56.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.17% over the past year.
ICCM shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.98%.
Measured over the past years, ICCM shows a very strong growth in Revenue. The Revenue has been growing by 23.59% on average per year.
EPS 1Y (TTM)20.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.05%
Revenue 1Y (TTM)25.98%
Revenue growth 3Y-5.86%
Revenue growth 5Y23.59%
Sales Q2Q%106.88%
3.2 Future
ICCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.22% yearly.
The Revenue is expected to grow by 94.35% on average over the next years. This is a very strong growth
EPS Next Y3.56%
EPS Next 2Y7.24%
EPS Next 3Y9.51%
EPS Next 5Y25.22%
Revenue Next Year11.03%
Revenue Next 2Y34.4%
Revenue Next 3Y45.17%
Revenue Next 5Y94.35%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ICCM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ICCM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.24%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
No dividends for ICCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ICECURE MEDICAL LTD
NASDAQ:ICCM (1/15/2025, 2:25:09 PM)
1.2314
-0.01 (-0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.73%
Inst Owner Change0%
Ins Owners54.17%
Ins Owner ChangeN/A
Market Cap67.46M
Analysts82
Price Target3.2 (159.87%)
Short Float %3.8%
Short Ratio1.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.7%
Min EPS beat(2)-4.58%
Max EPS beat(2)15.97%
EPS beat(4)3
Avg EPS beat(4)5.58%
Min EPS beat(4)-4.58%
Max EPS beat(4)15.97%
EPS beat(8)6
Avg EPS beat(8)6.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.65%
Min Revenue beat(2)-8.4%
Max Revenue beat(2)7.1%
Revenue beat(4)2
Avg Revenue beat(4)-3.16%
Min Revenue beat(4)-16.8%
Max Revenue beat(4)7.1%
Revenue beat(8)2
Avg Revenue beat(8)-14.9%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.51%
EPS NY rev (3m)-3.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.05%
Revenue NY rev (1m)-7.23%
Revenue NY rev (3m)-7.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.38 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.71 | ||
| P/tB | 6.71 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.07
BVpS0.18
TBVpS0.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -90.55% | ||
| ROE | -137.51% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.67% | ||
| FCFM | N/A |
ROA(3y)-58.73%
ROA(5y)-55.17%
ROE(3y)-74.66%
ROE(5y)-93.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.89%
GM growth 5Y-0.83%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.14% | ||
| Cap/Sales | 4% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.27 | ||
| Altman-Z | -3.69 |
F-Score4
WACC9.36%
ROIC/WACCN/A
Cap/Depr(3y)304.1%
Cap/Depr(5y)269.13%
Cap/Sales(3y)18.82%
Cap/Sales(5y)13.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.05%
EPS Next Y3.56%
EPS Next 2Y7.24%
EPS Next 3Y9.51%
EPS Next 5Y25.22%
Revenue 1Y (TTM)25.98%
Revenue growth 3Y-5.86%
Revenue growth 5Y23.59%
Sales Q2Q%106.88%
Revenue Next Year11.03%
Revenue Next 2Y34.4%
Revenue Next 3Y45.17%
Revenue Next 5Y94.35%
EBIT growth 1Y9.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.38%
OCF growth 3YN/A
OCF growth 5YN/A